4882万元收购一家公司,买断CLDN18.2核心双抗权利

动脉新医药
Jul 18

7月17日,美国天境生物(I-Mab)宣布达成最终协议,收购Bridge Health 100%股权。此次交易将为公司带来其CLDN18.2×4-1BB双抗Givastomig所使用的CLDN18.2亲本抗体在双特异性及多特异性应用(包括双抗、多抗和ADC)方面的上游权利,进一步巩固Givastomig的知识产权护城河。根据协议条款,天境生物将向Bridge Health股东支付180万美元预付款...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10